Defibrillation leads remain the Achilles heel of implantable cardioverter-defibrillators. As patients with implantable cardioverter-defibrillators are living longer and battery longevity increases, more durable leads are needed. The LEADR trial evaluated the novel, lumenless, small-diameter, OmniaSecure defibrillation lead and demonstrated favorable safety and efficacy profile as well as zero fractures through 12.7 ± 4.8 months and remains in clinical follow-up. To augment the clinical trial, advanced cardiac lead reliability modeling was used to project long-term lead durability.

Two or three decades ago, many considered the standard 12-lead electrocardiograms (ECGs) similarly as theoretical physics was seen at the end of 19th century: of some practical use but dull since everything was known making noticeable advances impossible. Indeed, various medical schools stopped studying and teaching ECGs, believing that only diagnostics by standard equipment was of any value.